The Prognostic Value of Nanog Overexpression in Lung Cancer: A Meta-Analysis

Table 4

Subgroup analysis of DFS by pathological type, publication year, NOS score, and country.

Subgroup	No. of studies	No. of patients	P value	Pooled HR (95% CI)	PHet	I^2 (%)
Pathological type
Adenocarcinoma	2	290	0.010	1.85 (1.16-2.96)	0.189	41.9%
Squamous cell carcinoma	1	48	≤0.001	3.76 (1.89-7.49)
Small cell carcinoma	1	50	0.085	1.26 (0.97-1.64)
Publication year
2010-2016	2	276	0.008	1.34 (1.08-1.67)	0.402	0.0%
2017	2	222	≤0.001	2.92 (2.00-4.26)	0.585	0.0%
NOS score
≤7	1	50	0.085	1.26 (0.97-1.64)
>7	3	448	0.001	2.21 (1.36-3.61)	0.061	64.2%
Country
China	0	0
Other	4	498	0. 006	1.86 (1.20-2.90)	0.004	77.2%

DFS, disease free survival; NO, number of sample size; NOS, Newcastle-Ottawa-Scale; HR, hazard ratio; CI, confidence interval.